DongKook Pharmaceutical Co., Ltd. (KOSDAQ: 086450)

Market Cap	709.65B
Revenue (ttm)	789.11B
Net Income (ttm)	61.64B
Shares Out	43.97M
EPS (ttm)	1,378.55
PE Ratio	11.71
Forward PE	10.75
Dividend	180.00 (1.12%)
Ex-Dividend Date	n/a

Volume	38,916
Open	16,250
Previous Close	16,320
Day's Range	16,070 - 16,400
52-Week Range	14,990 - 20,600
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 7, 2025

About DongKook Pharmaceutical

DongKook Pharmaceutical Co., Ltd. produces and sell pharmaceutical products in South Korea and internationally. The company offers non-prescription and prescription drugs, quasi drugs, medical devices, active pharmaceutical ingredients, and cosmetics. Its pipeline includes DKF-310, which is in preclinical trials for the treatment of dementia; DKM-413, used for anesthetic; DKF-361, used to treat hypertension; DKF-325, an anticoagulant; DKM-412 and DKM-420 to treat osteoarthritis; DKF-313, that is in clinical studies, indicated for benign prostat...

• Industry: Pharmaceutical Preparations
• Founded: 1968
• Employees: 1,131
• Stock Exchange: KOSDAQ
• Ticker Symbol: 086450

Financial Performance

In 2023, DongKook Pharmaceutical's revenue was 730.99 billion, an increase of 10.48% compared to the previous year's 661.65 billion. Earnings were 47.18 billion, a decrease of -10.82%.